发明名称 Compositions for treatment of attention deficit hyperactivity disorder
摘要 Therapeutic compositions and methods for treatment of attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD) include dosage forms that deliver a therapeutic amount of active drug in a delayed and controlled release formulation. The dosage form can be administered at night and drug release is delayed for from 5 to 8 hours or longer, followed by a prolonged release.
申请公布号 US9119809(B2) 申请公布日期 2015.09.01
申请号 US201414255529 申请日期 2014.04.17
申请人 Ironshore Pharmaceuticals & Development, Inc. 发明人 Lickrish David;Zhang Feng
分类号 A61K31/137;A61K9/16;A61K9/22;A61K9/32;A61K9/52;A61K9/58;A61K9/50;A61K31/4458 主分类号 A61K31/137
代理机构 Vinson & Elkins LLP 代理人 Vinson & Elkins LLP
主权项 1. A solid, oral pharmaceutical composition comprising a plurality of particles, each comprising: a core comprising an amphetamine or a pharmaceutical salt thereof and at least one pharmaceutically acceptable excipient; a sustained release layer enclosing the core; and a delayed release layer enclosing the sustained release layer, wherein when the composition is orally administered to a human subject, (i) there is a lag period of at least 6 hours during which the area under the curve of plasma concentration versus time (AUC0-6) of amphetamine or a pharmaceutical salt thereof is less than 10% of the total area under the curve at Tmax (AUC0-Tmax); and (ii) the time to Cmax (Tmax) is between 12 and 19 hours after administration.
地址 Camana Bay KY US